B-raf Kinase Inhibitor GSK2118436 as Therapy for Patients with Metastatic Melanoma and Other Solid TumorsB-raf Kinase Inhibitor GSK2118436 as Therapy for Patients with Metastatic Melanoma and Other Solid Tumors
Slides from a presentation at ASCO 2010 and transcribed comments from a recent interview with Steven J O’Day, MD (6/25/10)
Kefford R et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Proc ASCO 2010;Abstract 8503. |